In the stratification of patients with breast cancer with HER2 driver dependency, there was a notable incompatibility between conventional PAM50-based classification, classical pathological HER2 type designation, and proteogenomic-based integrative clustering. This evidence concerns the gene ERBB2 and breast cancer.